Evidence map›Paper›PMID 37292624›Full record

ArticlebioRxiv : the preprint server for biology2023

A new antibiotic from an uncultured bacterium binds to an immutable target.

Rhythm Shukla, Aaron J Peoples, Kevin C Ludwig, Sourav Maity, Maik G N Derks, Stefania de Benedetti, Annika M Krueger, Bram J A Vermeulen, Francesca Lavore, Rodrigo V Honorato and 15 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 4 countries.

Rhythm ShuklaNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Aaron J PeoplesNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Kevin C LudwigInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Sourav MaityMoleculaire Biofysica, Zernike Instituut, Rijksuniversiteit Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands.
Maik G N DerksNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Stefania de BenedettiInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Annika M KruegerInstitute for Physical and Theoretical Chemistry, University of Bonn, Bonn, Germany.
Bram J A VermeulenNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Francesca LavoreNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Rodrigo V HonoratoNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Fabian GreinInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Alexandre BonvinNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Ulrich KubitscheckInstitute for Physical and Theoretical Chemistry, University of Bonn, Bonn, Germany.
Eefjan BreukinkMembrane Biochemistry and Biophysics, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
Catherine AchornNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Anthony NittiNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Christopher J SchwalenNovartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
Amy L SpoeringNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Losee Lucy LingNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Dallas HughesNovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.
Moreno LelliMagnetic Resonance Center (CERM) and Department of Chemistry "Ugo Schiff", University of Florence, via Sacconi 6, Sesto Fiorentino, 50019 Italy.
Wouter H RoosMoleculaire Biofysica, Zernike Instituut, Rijksuniversiteit Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands.
Kim LewisAntimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA.
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Markus WeingarthNMR Spectroscopy, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Utrecht University · NLNovoBiotic Pharmaceuticals · USUniversity of Bonn · DEUniversity of Groningen · NLInteruniversity Consortium for Magnetic Resonance · ITNortheastern University · USNovartis (United States) · US

Funding

Uncultured bacteria for the discovery of novel antimicrobialsP01AI118687 · NIAID · NORTHEASTERN UNIVERSITY · PI LEWIS, KIM · 2016 to 2020
$8.9M
Discovering antimicrobials acting against MDR pathogensR01AI170962 · NIAID · NORTHEASTERN UNIVERSITY · PI LEWIS, KIM · 2022 to 2025
$4.5M
Drug Discovery from Slow Growing and Rare Microbial SpeciesR44AI091224 · NIAID · NOVOBIOTIC PHARMACEUTICALS, LLC · PI SPOERING, AMY LYNN · 2013 to 2015
$3.0M
Preclinical development of Novo29, a new antibioticR44AI136137 · NIAID · NOVOBIOTIC PHARMACEUTICALS, LLC · PI LING, LOSEE LUCY · 2019 to 2021
$3.0M
Drug Discovery from Slow Growing and Rare Microbial SpeciesR43AI091224 · NIAID · NOVOBIOTIC PHARMACEUTICALS, LLC · PI SPOERING, AMY LYNN · 2010 to 2011
$599k
Preclinical development of Novo29, a new antibioticR43AI136137 · NIAID · NOVOBIOTIC PHARMACEUTICALS, LLC · PI LING, LOSEE LUCY · 2018 to 2018
$231k
NIAID NIH HHS P01 AI118687NIAID NIH HHS R01 AI170962NIAID NIH HHS R43 AI091224NIAID NIH HHS R43 AI136137NIAID NIH HHS R44 AI091224NIAID NIH HHS R44 AI136137
6 · The paper itself

Abstract

Antimicrobial resistance is a leading mortality factor worldwide. Here we report the discovery of clovibactin, a new antibiotic, isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant bacterial pathogens without detectable resistance. Using biochemical assays, solid-state NMR, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors (C

Identifiers

PMID37292624
PMCPMC10245560
OpenAlexW4376645732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.